Skip to main content
Home > BC Innovations > Strategy

Chronological Index of : Strategy

 Current Issue
  • The Sharing Economy

    Pharma is opening up its libraries to draw in external partners

    In the latest iteration of open innovation, pharmas are starting to lower their guard and embark on large-scale compound-sharing programs with other companies and academics.

    Published on 12/8/2016
  • Table: Pharma compound-sharing deals

    The Sharing Economy Strategy Pharma compound-sharing deals Select pharma compound-sharing partnerships. Each partnership involves sharing, swapping or screening compounds from at least one pharma company's library.…

    Published on 12/8/2016
  • Figure: Commercialization gap

    China's dysfunctional patent flood Strategy Commercialization gap Although Chinese universities file many more patents each year than academic institutes in the U.S. and Europe, they lag behind when it comes to …

    Published on 11/17/2016
  • Figure: No contest

    China's dysfunctional patent flood Strategy No contest Chinese universities beat U.S. and U.K. universities by an order of magnitude when it comes to patenting their technologies. The chart shows the numbers of …

    Published on 11/17/2016
  • China's dysfunctional patent flood

    How poor patents hinder tech transfer in China

    A mountain of poor quality patents is hampering commercialization of Chinese science. The question is whether government reforms will change the landscape.

    Published on 11/17/2016
  • Editing the claims

    How Cellectis hopes its gene editing patents give it a leg up over CRISPR players

    Cellectis believes a pair of gene editing patents will give it a leg up over any of the players in the CRISPR IP dispute.

    Published on 11/10/2016
  • Box: Going, going, gone

    The next (re)generation Strategy Going, going, gone The failure of first-wave regenerative medicine companies still looms large for industry and investors. Three high-profile busts in the last three years could be …

    Published on 11/3/2016
  • Figure: Regenerative Venture

    The next (re)generation Strategy Regenerative Venture In the last decade, VC investment in regenerative medicine companies has been highly variable, but the last three years have seen a big uptick in private …

    Published on 11/3/2016
  • The next (re)generation

    Why investors both want and worry about regenerative medicine

    Despite scientific progress in regenerative medicine, stakeholders fear technical challenges and company missteps could turn off both investors and regulators.

    Published on 11/3/2016
  • Exosomes in the zone

    Academia and industry agree that exosomes are ready for prime time

    The rise in exosome knowledge has the field poised to deliver a possibly transformational technology for diagnostics, with therapeutic applications on their trail.

    Published on 10/13/2016
  • Figure: Exosome publications

    Exosomes in the zone Strategy Exosome publications The publication of exosome-related papers has risen by an order of magnitude since 2006, and the totals for 2016 through Oct. 11 have already surpassed 2015 totals…

    Published on 10/13/2016
  • Table: Companies chasing exosomes

    Exosomes in the zone Strategy Companies chasing exosomes At least 12 companies are pursuing therapeutics or diagnostics that utilize exosomes, including at least seven whose primary focus is exosome-based …

    Published on 10/13/2016
  • Table: Exosomes in fashion

    Exosomes in the zone Strategy Exosomes in fashion At least three new companies have been founded in the last two years based on exosome technology, and a fourth company, founded earlier, raised early stage …

    Published on 10/13/2016
  • Program in orbit

    Cancer Moonshot turbocharges drug combination research

    Among the slew of programs in Cancer Moonshot, the NCI's Drug Formulary stands out for adding a new dimension to combination testing that would have been hard to come by otherwise.

    Published on 9/22/2016
  • In the CRISPR tea leaves

    How deal flow is beginning to reveal CRISPR company strategies

    The deal flow by foundational CRISPR companies is providing clues into what they are prioritizing to take into the clinic.

    Published on 9/22/2016
  • Figure: 2 patents, 3 inventors, 4 companies

    In the CRISPR tea leaves Strategy 2 patents, 3 inventors, 4 companies The foundational CRISPR patents have undergone a series of licensing transactions, resulting in four therapeutically focused companies with …

    Published on 9/22/2016
  • Table: CRISPR collaborations

    In the CRISPR tea leaves Strategy CRISPR collaborations Select licensing and collaboration deals made by the four foundational CRISPR companies. Since December 2014, at least 17 partnerships or licensing deals were…

    Published on 9/22/2016
  • Box: Pedal to metal

    Program in orbit Strategy Pedal to metal On Sept. 7, the Cancer Moonshot Blue Ribbon Panel announced 10 recommendations in a report to the president's National Cancer Advisory Board that covered preclinical …

    Published on 9/22/2016
  • Figure: Phases of the moon

    Program in orbit Strategy Phases of the moon In June, the White House Cancer Moonshot Taskforce announced 12 government programs to help achieve the initiative's goal of a decade's worth of cancer discovery in five…

    Published on 9/22/2016
  • Mixed bag for PPPs

    Big companies go big for PPPs, but smaller companies still outnumber them

    While big pharma and big biotechs are the main players in public-private partnerships, smaller companies are getting in the game.

    Published on 8/25/2016
  • Figure: Big pharma and big biotech

    Mixed bag for PPPs Strategy Big pharma and big biotech Number of PPPs by big pharmas and big biotechs since 2011, including consortia and standard research partnerships. *2016 totals are calculated through Aug. 23.…

    Published on 8/25/2016
  • Figure: PPP share by company type

    Mixed bag for PPPs Strategy PPP share by company type Percentage of consortia and small research deals made by different company types since 2011. Big pharma companies continue to partner at a high rate, accounting…

    Published on 8/25/2016
  • Figure: PPP share by company type

    Mixed bag for PPPs Strategy PPP share by company type Percentage of consortia and small research deals made by different company types since 2011. Big pharma companies continue to partner at a high rate, accounting…

    Published on 8/25/2016
  • Figure: PPP share by company type

    Mixed bag for PPPs Strategy PPP share by company type Percentage of consortia and small research deals made by different company types since 2011. Big pharma companies continue to partner at a high rate, accounting…

    Published on 8/25/2016
  • Figure: Small company PPPs

    Mixed bag for PPPs Strategy Small company PPPs Number of PPP deals not involving big pharma or big biotech companies. Included are companies that have announced six or more partnerships since 2011, particularly …

    Published on 8/25/2016

< Previous   1  2  3  4  5  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993